Xcytrin motexafin gadolinium: Interim Phase II data

Interim data from a U.S. Phase II trial of Xcytrin showed that 5 patients exhibited clinical benefit, defined as stable disease or regressing disease following at least 6 months of follow-up. Also, 2 ...